These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21725649)

  • 21. Interventions to improve tolerability of local anesthetic intradetrusor Botulinum toxin injections: A systematic review.
    Faure Walker N; Macpherson F; Tasleem A; Rampal T
    Neurourol Urodyn; 2023 Jan; 42(1):23-32. PubMed ID: 36378811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
    Koh C; Melling CV; Jennings C; Lewis M; Goyal A
    J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Overactive bladder-which treatment when?].
    Pannek J
    Urologe A; 2017 Dec; 56(12):1532-1538. PubMed ID: 29043374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
    Sherif H; Khalil M; Omar R
    Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current management of refractory overactive bladder.
    Chen LC; Kuo HC
    Low Urin Tract Symptoms; 2020 May; 12(2):109-116. PubMed ID: 32073742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
    Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
    Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients.
    Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA
    Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review.
    Zhang Y; Ji F; Liu E; Wen JG
    Urol Int; 2021; 105(11-12):929-934. PubMed ID: 34130295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The management of overactive bladder refractory to medical therapy.
    Robinson D; Giarenis I; Cardozo L
    Maturitas; 2013 May; 75(1):101-4. PubMed ID: 23415926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electromotive drug administration for treatment of therapy-refractory overactive bladder.
    Gauruder-Burmester A; Biskupskie A; Rosahl A; Tunn R
    Int Braz J Urol; 2008; 34(6):758-64. PubMed ID: 19111081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.
    Apostolidis A; Rahnama'i MS; Fry C; Dmochowski R; Sahai A
    Neurourol Urodyn; 2016 Feb; 35(2):293-8. PubMed ID: 26872570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review].
    Henriet B; Roumeguère T
    Rev Med Brux; 2015; 36(1):29-37. PubMed ID: 25856969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Standard pharmacological treatment and new therapies for overactive bladder].
    Del Popolo G; Mencarini M; Li Marzi V
    Urologia; 2012; 79(1):6-13. PubMed ID: 22344568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder.
    Juszczak K; Adamczyk P; Maciukiewicz P; Drewa T
    Pharmacol Rep; 2018 Dec; 70(6):1133-1138. PubMed ID: 30317128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
    Leong RK; De Wachter SG; van Kerrebroeck PE
    Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.
    Dowson C; Watkins J; Khan MS; Dasgupta P; Sahai A
    Eur Urol; 2012 Apr; 61(4):834-9. PubMed ID: 22204745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.